array(25) {
["id"]=>
string(5) "79830"
["name"]=>
string(6) "習(xí)勉"
["avatar"]=>
string(72) "https://img.39yst.com/uploads/19763/e2268f76c577bb841bbb1447723aa9b4.jpg"
["status"]=>
string(1) "0"
["rank_type"]=>
string(1) "1"
["duodian_main_id"]=>
string(1) "0"
["miaopai"]=>
string(0) ""
["graphic_consult"]=>
string(1) "0"
["position"]=>
string(12) "主任醫(yī)師"
["introduction"]=>
string(8283) "一、基本情況
職稱:主任醫(yī)師、教授、博士生導(dǎo)師
職務(wù):廣東省食管癌研究所副所長
專業(yè)特長:食管癌、肝癌等胸腹部腫瘤的放射治療
門診時間:周二上午、下午(越秀院區(qū)),周四上午(黃埔院區(qū))
主要研究方向:1、食管癌的放化綜合治療;2、肝癌的精準(zhǔn)放療。
?
二、個人簡介
主要從事食管癌、肝癌等胸腹部腫瘤的放射治療。2011年入選腫瘤防治中心優(yōu)秀青年人才計劃,2015年入選臨床醫(yī)學(xué)科學(xué)家培養(yǎng)計劃,2016-2017年在美國M.D. Anderson腫瘤中心訪問學(xué)習(xí),為腫瘤防治中心食管癌單病種首席專家團(tuán)隊核心成員兼秘書,2021.12月起擔(dān)任廣東省食管癌研究所副所長。主持及參與食管癌、肝癌、肺癌多項臨床試驗,作為第一或通訊作者發(fā)表SCI論著50余篇,承擔(dān)國家自然科學(xué)基金、廣東省自然科學(xué)基金、廣州市科技計劃等多項課題。
?
三、工作經(jīng)歷
2007.08-2010.12 ?中山大學(xué)腫瘤防治中心放療科,住院醫(yī)師
2010.12-2015.12 ?中山大學(xué)腫瘤防治中心放療科,主治醫(yī)師
2015.12-2020.12 ?中山大學(xué)腫瘤防治中心放療科,副主任醫(yī)師
2016-2017? ? ? ? ? ? 美國M.D. Anderson腫瘤中心,訪問學(xué)者
2020.12-至今? ? ? ? 中山大學(xué)腫瘤防治中心放療科,主任醫(yī)師
2023.12-至今? ? ? ? 中山大學(xué)腫瘤防治中心放療科,教授
?
四、學(xué)術(shù)任職
中國醫(yī)藥教育協(xié)會腫瘤放療專委會常委;
廣東省抗癌協(xié)會食管癌專業(yè)委員會常委;
廣東省臨床醫(yī)學(xué)學(xué)會消化腫瘤綜合治療青年專業(yè)委員會副主委;
廣東省器官醫(yī)學(xué)與技術(shù)學(xué)會肝癌多學(xué)科綜合治療專委會副主委;
廣東省肝臟病學(xué)會綜合治療專委會常委;
廣東省抗癌協(xié)會肝癌專業(yè)委員會青委會常委;
廣東省醫(yī)藥質(zhì)量管理協(xié)會放射腫瘤學(xué)專委會常委;
中國抗癌協(xié)會食管癌專業(yè)委員會委員;
國際肝膽胰協(xié)會中國分會肝膽胰MDT專業(yè)委員會委員;
中華醫(yī)學(xué)會/中國醫(yī)師協(xié)會放療專委會肝癌學(xué)組、食管癌學(xué)組委員。
?
五、近年已發(fā)表代表性第一/通訊作者論文
1. Chen?B#, Liu S#, Zhu Y#, Wang R#, Cheng X, Chen B, Dragomir MP, Zhang Y, Hu Y, Liu M, Li Q*, Yang H*, Xi M*. Predictive role of ctDNA in esophageal squamous cell carcinoma receiving definitive chemoradiotherapy combined with toripalimab. Nat Commun. 2024;15(1):1919.
2. Zhu Y#, Wen J#, Li Q#, Chen B#, Zhao L#, Liu S, Yang Y, Wang S, Lv Y, Li J, Zhang L, Hu Y*, Liu M*, Xi M*.?Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trial.?Lancet Oncol. 2023;24(4):371-382.
3. Zhou S#, Wang Y#, Zhang R#, Zeng W#, Liu S, Liu S, Liu M, Yang H*, Xi M*.?Association of Sialic Acid-Binding Immunoglobulin-Like Lectin 15 With Phenotypes in Esophageal Squamous Cell Carcinoma in the Setting of Neoadjuvant Chemoradiotherapy.?JAMA Netw Open. 2023;6(1):e2250965.
4. Chen R#, Liu Q#, Li Q#, Zhu Y#, Zhao L#, Liu S#, Chen B, Liu M, Hu Y, Lin T, Li J, Chen J, Lv Y, Fu J*, Xi M*, Yang H*. A phase II clinical trial of toripalimab combined with?neoadjuvant chemoradiotherapy in locally advanced?esophageal squamous cell carcinoma (NEOCRTEC1901). EClinicalMedicine.?2023;62:102118.
5. Cheng X#, Chen B#, Wang S#, Zhang J, Zhu J, Liu M, Liu S*, Xi M*. Association between lymphopenia and survival outcomes in esophageal carcinoma patients receiving combined immunotherapy and chemoradiotherapy. Oncologist. 2023;28(8):e606-e616.
6. Wang Y#, Li Q#, Zhang L, Liu S, Zhu J, Yang Y, Liu M, Zhang Y*, Xi M*.?Efficacy and dose-response relationship of stereotactic body radiotherapy for abdominal lymph node metastases from hepatocellular carcinoma.?Oncologist. 2023;28(6):e369-e378.
7. Wen J#, Fang S#, Hu Y#, Xi M#, Weng Z, Pan C, Luo K, Ling Y, Lai R, Xie X, Lin X, Lin T, Chen J, Liu Q*, Fu J*, Yang H*. Impacts of neoadjuvant chemoradiotherapy on the immune landscape of esophageal squamous cell carcinoma. EBioMedicine. 2022;86: 104371.
8. Liu S, Luo L, Zhao L, Zhu Y, Liu H, Li Q, Cai L, Hu Y, Qiu B, Zhang L, Shen J, Yang Y, Liu M*, Xi M*. Induction chemotherapy followed by definitive chemoradiotherapy versus chemoradiotherapy alone in esophageal squamous cell carcinoma: a randomized phase II trial. Nat Commun. 2021; 12(1): 4014.
9. Xu?H, Lin M, Hu Y, Zhang L, Li Q, Zhu J, Wang S*, Xi M*. Lymphopenia during definitive chemoradiotherapy in esophageal squamous cell carcinoma: Association with dosimetric parameters and patient outcomes. Oncologist. 2021;?26(3):?e425-434.
10. Pan C, Wang Y, Liu Q, Hu Y, Fu J, Xie X, Zhang S*, Xi M*, Wen J*. Phenotypic profiling and prognostic significance of immune infiltrates in esophageal squamous cell carcinoma. OncoImmunology. 2021; 10(1): 1883890.
11. Liu S, Wen J, Yang H, Li Q, Chen Y, Zhu C, Fang W, Yu Z, Mao W, Xiang J, Han Y, Zhao L, Liu H, Hu Y, Liu M, Fu J*, Xi M*. Recurrence patterns after neoadjuvant chemoradiotherapy compared with surgery alone in oesophageal squamous cell carcinoma: results from the multicenter phase III trial NEOCRTEC5010. Eur J Cancer. 2020;138: 113-121.
12. Zhou S, Yang H, Zhang J, Wang J, Liang Z, Liu S, Li Y, Pan Y, Zhao L, Xi M*. Changes in indoleamine 2,3-dioxygenase 1 expression and CD8+ tumor-infiltrating lymphocytes after neoadjuvant chemoradiation therapy?and prognostic significance in esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2020; 108(1):286-294.
13. Zhou S, Liu S, Lin C, Li Y, Ye L, Wu X, Jian Y, Dai Y, Ouyang Y, Zhao L, Liu M, Song L*, Xi M*.?TRIB3 confers radiotherapy resistance in esophageal squamous cell carcinoma by stabilizing TAZ.?Oncogene. 2020;?39(18):?3710-3725.
14. Lan K, Zhu J, Zhang J, Zhou S, Yang Y, Feng Z, Zhang L, Wang S*, Xi M*. Propensity score-based comparison of survival and radiation pneumonitis after definitive chemoradiation for esophageal cancer: Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy. Radiother Oncol. 2020; 149: 228-235.
15. Xi M,?Yang Y, Zhang L, Yang H, Merrell KW, Hallemeier?CL,?Shen RK, Haddock MG, Hofstetter WL,?Maru?DM,?Ho L,?Wu CC, Liu M, Lin SH.?Multi-institutional analysis of recurrence and survival after neoadjuvant chemoradiotherapy of esophageal cancer: the impact of histology on recurrence patterns and outcomes.?Ann Surg. 2019;?269(4):?663-670.
17. Xi M,?Hallemeier?CL,?Merrell?KW, Liao Z, Murphy MAB,?Ho L, Hofstetter WL, Mehran?R, Lee?JH, Bhutani?MS,?Weston?B, Maru?DM, Komaki R, Ajani?JA, Lin SH.?Recurrence risk stratification after preoperative chemoradiation?of esophageal adenocarcinoma.?Ann Surg. 2018;?268(2):?289-295.
18. Xi M,?Liao Z, Deng W, Xu C, Komaki R, Blum M, Hofstetter WL, Ho L, Lin SH.?A prognostic scoring model for the utility of induction chemotherapy prior to neoadjuvant chemoradiotherapy in esophageal cancer.?J Thorac Oncol. 2017; 12(6): 1001-1010.
19. Xi M,?Liao Z, Hofstetter WL,?Komaki R, Ho L, Lin SH.?18F-FDG?PET response after induction chemotherapy can predict who will benefit from subsequent esophagectomy after chemoradiotherapy for esophageal adenocarcinoma. J Nucl Med. 2017; 58(11):?1756-1763.
20. Xi?M,?Xu C, Liao Z, Chang JY, Gomez DR, Jeter M, Cox JD, Komaki R, Mehran R, Blum MA, Hofstetter WL, Maru DM, Bhutani MS, Lee JH, Weston B, Ajani JA, Lin SH. Comparative outcomes after definitive chemoradiotherapy using proton beam therapy versus intensity-modulated radiation therapy for esophageal cancer: a retrospective,?single-institutional analysis. Int J Radiat Oncol Biol Phys. 2017;?99(3): 667-676.
21. Xi M,?Liao Z, Deng W, Komaki R, Ho L, Lin SH.?Recursive partitioning analysis identifies pretreatment risk groups for the utility of induction chemotherapy prior to definitive chemoradiotherapy in esophageal cancer. Int J Radiat Oncol Biol Phys. 2017; 99(2): 407-416.
22. Xi?M,?Xu C, Liao Z, Hofstetter WL, Blum Murphy M, Maru DM, Bhutani MS, Lee JH, Weston B, Komaki?R, Lin SH.?The impact of histology on recurrence patterns in esophageal cancer treated with definitive chemoradiotherapy. Radiother Oncol. 2017;?124(2):?318-324.
?
?
?
更新時間:2024.04.30"
["adept"]=>
string(51) "食管癌、肝癌等胸腹部腫瘤的放射治療"
["duodian_doctor_id"]=>
string(6) "115173"
["source_from"]=>
string(12) "醫(yī)院官網(wǎng)"
["is_jingxuan"]=>
string(1) "0"
["title_num"]=>
string(0) ""
["created"]=>
string(10) "1754967849"
["doctor_title"]=>
string(12) "主任醫(yī)師"
["is_seniority"]=>
int(1)
["province_id"]=>
int(0)
["city_id"]=>
int(0)
["hospital_sort"]=>
string(2) "32"
["hospital"]=>
array(1) {
[0]=>
array(31) {
["id"]=>
string(5) "19763"
["name"]=>
string(30) "中山大學(xué)腫瘤防治中心"
["grade_id"]=>
string(1) "2"
["grade"]=>
string(0) ""
["type"]=>
string(1) "1"
["duodian_hospital_id"]=>
string(3) "814"
["address"]=>
string(27) "廣州市東風(fēng)東路651號"
["is_gongli"]=>
string(1) "1"
["logo"]=>
string(72) "http://pic.39yst.com/group2/M00/8B/F7/Co2PPWKfAdKACBy1AABiOqd-PC074.jpeg"
["is_pay"]=>
string(1) "0"
["pic"]=>
string(72) "http://pic.39yst.com/group2/M00/99/67/Co2PPWZ-H3qABl2PAAK_8SuU6HY43.jpeg"
["is_top100"]=>
string(1) "1"
["parent_areaid"]=>
string(2) "19"
["areaid"]=>
string(4) "1601"
["top100_sort"]=>
string(2) "32"
["guide"]=>
string(0) ""
["tel"]=>
string(38) "020-87673713,020-87765368 "
["is_seniority"]=>
string(1) "1"
["hospital_title"]=>
string(6) "三甲"
["hospital_grade_id"]=>
string(1) "2"
["hospital_type"]=>
string(12) "綜合醫(yī)院"
["hospital_type_id"]=>
string(1) "1"
["hospital"]=>
string(30) "中山大學(xué)腫瘤防治中心"
["department_id"]=>
string(2) "43"
["duodian_department_id"]=>
string(5) "11854"
["duodian_department_pid"]=>
string(5) "11845"
["department_name"]=>
string(9) "放療科"
["standard_department_id"]=>
string(2) "43"
["parent_standard_department_id"]=>
string(1) "6"
["hospital_department"]=>
string(9) "放療科"
["duty"]=>
array(0) {
}
}
}
["version"]=>
int(40)
["isHaveSource"]=>
int(0)
["duty"]=>
string(0) ""
}